CSL Behring has announced another donation of factor product to the World Federation of Hemophilia (WFH) in connection with World Hemophilia Day on April 17. The therapies will be used to treat patients in developing countries and who have certain types of bleeding disorders. The donation supports WFH’s progress in improving the diagnosis and treatment of bleeding disorders through its Global Alliance for Progress (GAP) program. The company’s current donation includes product used to treat von Willebrand disease and hemophilia. The volume of product donated is approximately 1 million international units (IUs).
CSL Behring first committed to the GAP program in 2009. The donations were made in installments of two million IUs three times during the life of the contract, for a total of six million IUs. CSL Behring renewed its product donation contract with WFH for the period 2013 through 2016.
“CSL Behring is pleased and proud to support the World Federation of Hemophilia as a long-standing contributor to GAP,” said Paul Perreault, President of CSL Behring. “WFH is committed to improving the lives of patients with bleeding disorders in areas of the world where the needs are greatest. Their mission aligns closely with that of CSL Behring, as we also focus on the unmet needs of patients with rare and serious bleeding disorders and constantly seek to make meaningful differences in their lives and their communities.”
Source: CSL Behring news release dated April 3, 2013
